Cassava Sciences is a clinical-stage drug development company. The company focuses on developing new product candidates and to guide these through various regulatory and development pathways in preparation for their potential commercialization. The company's clinical-stage biopharmaceutical assets include: PTI-125, which is its product candidate for the treatment of Alzheimer's disease; and PTI-125Dx, which it is developing as a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company owns worldwide rights to PTI-125 and PTI-125Dx, without royalty obligations to any third party.
INmune Bio is an early stage pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. The company's proprietary is to focus on the innate immune system that include natural killer cells (NK cells), myeloid derived suppressor cells (MDSC cells) and dendritic cells. The company's existing drug platforms are: INKmune which primes NK cells and INB03 which down regulates MDSC cells.
Quantum Research Group, LLC is a New York City-based sponsored equity research and distribution company.
The company focuses on emerging growth public companies that are seeking detailed equity analysis and extensive distribution aimed at the investment community.
Our distribution partners include dozens of the leading financial platforms, including Thomson Reuters, Standard & Poor's Capital IQ, Bloomberg, Zacks, NASDAQ, Yahoo! Finance, and NYSE Connect.
Our reports reach over 20 channels, with our top five platforms reaching over 818,000 readers from both the buy-side and sell-side.
Quantum has a strong proven track record in the fields of Biotechnology/Pharma, Technology, Telecommunication, Media/News, Transportation, Insurance and Fintech.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.